{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:41:00Z","timestamp":1792896060631,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This trial aimed to evaluate the efficacy of sirolimus in addition to cyclosporine (CSP) and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis after nonmyeloablative conditioning for HLA class I or II mismatched hematopoietic cell transplantation (HCT). Eligible patients had hematologic malignancies treatable by allogeneic HCT. Conditioning consisted of fludarabine (90 mg\/m2) and 2 to 3 Gy total body irradiation. GVHD prophylaxis comprised cyclosporine, mycophenolate mofetil, and sirolimus. The primary objective was to determine whether the cumulative incidence of grade 2 to 4 acute GVHD could be reduced to &amp;lt;70% in HLA class I or II mismatched HCT. The study was closed on December 20, 2018. Seventy-seven participants were recruited between April 14, 2011, and December 12, 2018, of whom 76 completed the study intervention. Median follow-up was 47 months (range, 4-94 months). The cumulative incidence of grade 2 to 4 acute GVHD at day 100 was 36% (95% confidence interval [CI], 25-46), meeting the primary end point. The cumulative incidence of nonrelapse morality, relapse\/progression, and overall survival was 18% (95% CI, 9-27), 30% (interquartile range, 19-40), and 62% (95% CI, 50-73) after 4 years. In conclusion, the addition of sirolimus to cyclosporine and mycophenolate mofetil resulted in a lower incidence of acute GVHD, thus translating into superior overall survival compared with historical results. This trial was registered at www.clinicaltrials.gov as #NCT01251575.<\/jats:p>","DOI":"10.1182\/blood.2020005338","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T20:44:47Z","timestamp":1593549887000},"page":"1499-1506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen\u2013mismatched donors"],"prefix":"10.1182","volume":"136","author":[{"given":"Brian","family":"Kornblit","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Haematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-435X","authenticated-orcid":false,"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels S.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Maris","sequence":"additional","affiliation":[{"name":"Colorado Blood Cancer Institute, Denver, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Chauncey","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; and"},{"name":"VA Puget Sound Health Care System, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie W.","family":"Petersdorf","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-3607","authenticated-orcid":false,"given":"Ann E.","family":"Woolfrey","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1631-0911","authenticated-orcid":false,"given":"Mary E. D.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9343-4099","authenticated-orcid":false,"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-9739","authenticated-orcid":false,"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2020092411284454100_B1","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"issue":"4","key":"2020092411284454100_B2","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","article-title":"Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2020092411284454100_B3","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020092411284454100_B4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.beha.2017.09.003","article-title":"Which factors influence the development of GVHD in HLA-matched or mismatched transplants?","volume":"30","author":"Petersdorf","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"2020092411284454100_B5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2020092411284454100_B6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.bbmt.2009.11.004","article-title":"Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial","volume":"16","author":"Nakamae","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020092411284454100_B7","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.bbmt.2019.06.029","article-title":"Effect of sirolimus on immune reconstitution following myeloablative allogeneic stem cell transplantation: an ancillary analysis of a randomized controlled trial comparing tacrolimus\/sirolimus and tacrolimus\/methotrexate (Blood and Marrow Transplant Clinical Trials Network\/BMT CTN 0402)","volume":"25","author":"Gooptu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020092411284454100_B31","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"issue":"23","key":"2020092411284454100_B32","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020092411284454100_B8","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"2020092411284454100_B9","first-page":"515","article-title":"Graft-versus-host disease","volume-title":"Hematopoietic Cell Transplantation","author":"Sullivan","year":"1999","edition":"2nd ed"},{"issue":"6","key":"2020092411284454100_B10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"8","key":"2020092411284454100_B11","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"2020092411284454100_B12","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bbmt.2015.05.028","article-title":"HLA mismatch is associated with worse outcomes after unrelated donor reduced-intensity conditioning hematopoietic cell transplantation: an analysis from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Verneris","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020092411284454100_B13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2016.11.009","article-title":"Impact of human leukocyte antigen allele mismatch in unrelated bone marrow transplantation with reduced-intensity conditioning regimen","volume":"23","author":"Yokoyama","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020092411284454100_B14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41409-019-0434-3","article-title":"Clinical significance of low-dose total body irradiation in HLA-mismatched reduced-intensity stem cell transplantation","volume":"54","author":"Fujiwara","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020092411284454100_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bmt.2014.220","article-title":"GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT","volume":"50","author":"Parody","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2020092411284454100_B15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"2020092411284454100_B16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2020092411284454100_B17","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020092411284454100_B18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2020092411284454100_B19","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2020092411284454100_B20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current use and trends in hematopoietic cell transplantation in the United States","volume":"23","author":"D\u2019Souza","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020092411284454100_B21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/bmt.2014.312","article-title":"Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants","volume":"50","author":"Passweg","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2020092411284454100_B22","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2020092411284454100_B23","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"2020092411284454100_B24","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/bloodadvances.2019000627","article-title":"Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy","volume":"3","author":"Solomon","year":"2019","journal-title":"Blood Adv"},{"issue":"26","key":"2020092411284454100_B25","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020092411284454100_B26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2020092411284454100_B27","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/cncr.30180","article-title":"Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation","volume":"122","author":"Gaballa","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"2020092411284454100_B28","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41409-018-0279-1","article-title":"Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide","volume":"54","author":"Sugita","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020092411284454100_B29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jamaoncol.2019.3541","article-title":"Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis","volume":"5","author":"Gagelmann","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"2020092411284454100_B30","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/13\/1499\/1758801\/bloodbld2020005338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/13\/1499\/1758801\/bloodbld2020005338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T15:31:17Z","timestamp":1600961477000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/13\/1499\/461231\/Sirolimus-with-CSP-and-MMF-as-GVHD-prophylaxis-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":33,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020005338","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]}}}